Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Short-term Investments (2016 - 2023)

Historic Short-term Investments for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Q3 2023 value amounting to $788000.0.

  • Ironwood Pharmaceuticals' Short-term Investments fell 3696.0% to $788000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $788000.0, marking a year-over-year decrease of 3696.0%. This contributed to the annual value of $1.3 million for FY2022, which is 0.0% changed from last year.
  • Ironwood Pharmaceuticals' Short-term Investments amounted to $788000.0 in Q3 2023, which was down 3696.0% from $788000.0 recorded in Q2 2023.
  • Ironwood Pharmaceuticals' Short-term Investments' 5-year high stood at $11.3 million during Q2 2021, with a 5-year trough of $788000.0 in Q2 2023.
  • For the 5-year period, Ironwood Pharmaceuticals' Short-term Investments averaged around $2.8 million, with its median value being $1.3 million (2021).
  • Its Short-term Investments has fluctuated over the past 5 years, first tumbled by 9748.28% in 2019, then soared by 80096.0% in 2021.
  • Ironwood Pharmaceuticals' Short-term Investments (Quarter) stood at $1.2 million in 2019, then skyrocketed by 38.8% to $1.7 million in 2020, then dropped by 25.07% to $1.3 million in 2021, then changed by 0.0% to $1.3 million in 2022, then plummeted by 39.38% to $788000.0 in 2023.
  • Its last three reported values are $788000.0 in Q3 2023, $788000.0 for Q2 2023, and $1.2 million during Q1 2023.